Cellectis (NASDAQ:CLLS) Upgraded at Clear Str

Clear Str upgraded shares of Cellectis (NASDAQ:CLLS) to a strong-buy rating in a research report released on Tuesday,Zacks.com reports.

CLLS has been the subject of a number of other reports. Wells Fargo & Company reaffirmed a “positive” rating and issued a $4.00 price target on shares of Cellectis in a report on Monday, October 20th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cellectis in a report on Wednesday, October 8th. Wall Street Zen upgraded Cellectis to a “hold” rating in a research report on Saturday, September 20th. Finally, Barclays increased their price target on shares of Cellectis from $4.00 to $8.00 and gave the stock an “overweight” rating in a report on Friday, October 17th. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Cellectis currently has a consensus rating of “Moderate Buy” and an average price target of $6.00.

Cellectis Trading Down 0.1%

Shares of NASDAQ:CLLS opened at $4.83 on Tuesday. The company has a current ratio of 1.49, a quick ratio of 1.49 and a debt-to-equity ratio of 0.63. The company has a 50-day moving average price of $4.21 and a two-hundred day moving average price of $3.13. Cellectis has a twelve month low of $1.10 and a twelve month high of $5.48.

Cellectis (NASDAQ:CLLS) last announced its quarterly earnings results on Friday, November 7th. The biotechnology company reported $0.01 EPS for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.11. Cellectis had a negative net margin of 58.06% and a negative return on equity of 51.22%. The company had revenue of $37.16 million for the quarter, compared to analysts’ expectations of $8.22 million. On average, equities analysts predict that Cellectis will post -0.46 EPS for the current year.

Hedge Funds Weigh In On Cellectis

A number of institutional investors have recently made changes to their positions in CLLS. Long Focus Capital Management LLC increased its stake in Cellectis by 2.2% in the first quarter. Long Focus Capital Management LLC now owns 4,717,293 shares of the biotechnology company’s stock valued at $5,849,000 after acquiring an additional 100,000 shares during the last quarter. OLD Mission Capital LLC purchased a new position in shares of Cellectis during the 1st quarter valued at about $31,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in Cellectis by 228.4% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 4,722,664 shares of the biotechnology company’s stock worth $5,856,000 after buying an additional 3,284,409 shares during the last quarter. Citadel Advisors LLC purchased a new stake in Cellectis in the third quarter worth approximately $633,000. Finally, Millennium Management LLC grew its position in Cellectis by 61.9% during the third quarter. Millennium Management LLC now owns 57,740 shares of the biotechnology company’s stock valued at $165,000 after acquiring an additional 22,080 shares during the last quarter. Institutional investors own 63.90% of the company’s stock.

Cellectis Company Profile

Cellectis is a clinical‐stage biopharmaceutical company specializing in the development of gene‐edited cell therapies for oncology. Founded in 1999 and headquartered in Paris, France, the company also maintains operations in New York City and Raleigh, North Carolina. Cellectis applies its proprietary TALEN genome editing platform to engineer allogeneic chimeric antigen receptor T‐cell (CAR‐T) candidates designed to target blood cancers and solid tumors.

The company’s core business activities encompass the discovery, development and manufacturing of off‐the‐shelf immunotherapies.